Rugo HS, Andre F, Yamashita T, Cerda H, et al. Time Course and Management of Key Adverse Events During the Randomized Phase 3
SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With
HR-Positive Advanced Breast Cancer. Ann Oncol 2020 May 13. pii: S0923-7534(20)39798.
PMID: 32416251